NOVEL TRENDS IN ANTIPSYCHOTIC DRUG DEVELOPMENT
DOI:
https://doi.org/10.56782/pps.112Keywords:
atypical antipsychotic drugs, antipsychotics, schizophrenia, single-target agents, multi-target agentsAbstract
Schizophrenia is a severe, chronic mental illness that affects approximately 1% of the population. It is associated with a shortened lifespan and significant impairments in social and vocational functioning. Multiple domains of symptoms, e.g. positive and negative symptoms as well as cognitive deficits demand a complex approach to treatment. Results of recent large-scale studies comparing the effectiveness of typical versus atypical antipsychotics appear to indicate that second generation agents are neither more effective, nor associated with better cognitive or social outcomes. The rational development of intentionally designed multi-target agents may solve these therapeutic problems, resulting in the next generation of CNS drugs.
Downloads
References
Bilikiewicz A., Psychiatria. Podręcznik dla studentów medycyny, PZWL 2006, 270–272.
Diagnostic and statistical manual of mental disorders, Fifth Edition. Arlington, VA, American Psychiatric Association 2013, 87–122.
Janiec W., Farmakodynamika. Podręcznik dla studentów farmacji, PZWL 2008, 194–195.
Carpenter W.T., Koenig J.I. Neuropsychopharmacol. 2008, 33, 2061−2079. DOI: https://doi.org/10.1038/sj.npp.1301639
van Os J., Kapur S. Lancet 2009, 374, 635−645. DOI: https://doi.org/10.1016/S0140-6736(09)60995-8
Moller H.J. World J. Biol. Psychiatry 2005, 6, 247–263. DOI: https://doi.org/10.1080/15622970500316674
Khan A., Lindenmayer J.P., Opler M., Kelley M.E., White L., Compton M., Gao Z., Harvey P.D. Schizophr. Res. Cog. 2014, 1, 53–89 DOI: https://doi.org/10.1016/j.scog.2014.01.002
McGrath J., Saha S., Chant D., Welham J. Epidemiol. Rev. 2008, 30, 67–76. DOI: https://doi.org/10.1093/epirev/mxn001
Castle D.J., Wessely S., Murray R.M., Br. J. Psychiatry 1993, 162, 658–664. DOI: https://doi.org/10.1192/bjp.162.5.658
Perala J., Suvisaari J., Saarni S.I., Arch. Gen. Psychiatry 2007, 64, 19–28. DOI: https://doi.org/10.1001/archpsyc.64.1.19
Roy M.A., Maziade M., Labbe A., Merette C., Schizophr. Res. 2001, 47, 141–147. DOI: https://doi.org/10.1016/S0920-9964(99)00231-5
Beauchamp G., Gagnon A., Soc. Psychiatry Psychiatr. Epidemiol. 2004, 39, 1017–1022. DOI: https://doi.org/10.1007/s00127-004-0844-3
Khashan A.S., Abel K.M., McNamee R., Arch. Gen. Psychiatry 2008, 65, 146–152. DOI: https://doi.org/10.1001/archgenpsychiatry.2007.20
Brown A.S.. Schizophr. Bull. 2006, 32, 200–202. DOI: https://doi.org/10.1093/schbul/sbj052
Welham J., Isohanni M., Jones P., McGrath J., Schizophr. Bull. 2009, 35, 603–623. DOI: https://doi.org/10.1093/schbul/sbn084
Woodberry K.A., Giuliano A.J., Seidman L.J., Am. J. Psychiatry 2008, 165, 579–587. DOI: https://doi.org/10.1176/appi.ajp.2008.07081242
Zammit S., Allebeck P., David A.S., Arch. Gen. Psychiatry 2004, 61, 354–360. DOI: https://doi.org/10.1001/archpsyc.61.4.354
Krabbendam L., van Os J., Schizophr. Bull. 2005, 31, 795–799. DOI: https://doi.org/10.1093/schbul/sbi060
Veling W., Susser E., van Os J., Mackenbach, J.P., Selten, J.P., Hoek, H.W., Am J Psychiatry 2008, 165, 66–73. DOI: https://doi.org/10.1176/appi.ajp.2007.07030423
D’Souza D.C., Perry E., MacDougall L., Neuropsychopharmacol. 2004, 29, 1558–1572. DOI: https://doi.org/10.1038/sj.npp.1300496
Arendt M., Rosenberg R., Foldager L., Perto G., Munk-Jorgensen P., Br. J. Psychiatry 2005, 187, 510–515. DOI: https://doi.org/10.1192/bjp.187.6.510
Ross C., Margolis R.L., Reading S.A.J., Pletnikov M., Coyle Jt. Neuron. 2006, 52, 139–153. DOI: https://doi.org/10.1016/j.neuron.2006.09.015
Walsh T., McClellan J.M., McCarthy S.E., Science 2008, 320, 539–543. DOI: https://doi.org/10.1126/science.1155174
Moskvina V., Craddock N., Holmans P., Mol. Psychiatry. 2009, 14, 252–260. DOI: https://doi.org/10.1038/mp.2008.133
Wohl M., Gorwood P., Eur. Psychiatry 2007, 22, 22–26. DOI: https://doi.org/10.1016/j.eurpsy.2006.08.007
van Os J., Rutten B.P., Poulton R., Schizophr. Bull. 2008, 34, 1066–1082. DOI: https://doi.org/10.1093/schbul/sbn117
Kasperska D., Murawiec S., Psychiatria i Psychoterapia 2011, Tom 7, Nr 1, 21–30.
Davis K.L., Kahn R.S., Ko G., Davidson M., Am. J. Psychiatry 1991, 148, 1474–1486. DOI: https://doi.org/10.1176/ajp.148.11.1474
Howes O., Kapur S., Schizophr. Bull. 2009, 35, 549–562. DOI: https://doi.org/10.1093/schbul/sbp006
Tsoi D.T.Y., Hunter M.D., Woodruff P.W.R., Psychiatry 2008, 7, 404–409. DOI: https://doi.org/10.1016/j.mppsy.2008.07.010
Tandon R., Nasrallah H.A., Keshavan M.S., Schizophr. Res. 2010, 122, 1–23. DOI: https://doi.org/10.1016/j.schres.2010.05.025
Tandon R., Nasrallah H.A., Keshavan M.S., Schizophr. Res. 2009, 110, 1–23. DOI: https://doi.org/10.1016/j.schres.2009.03.005
Swartz M.S., Perkins D.O., Stroup T.S., Am. J. Psychiatry 2007, 164, 428–436. DOI: https://doi.org/10.1176/ajp.2007.164.3.428
Davidson M., Galderisi S., Weiser M., Am. J. Psychiatry 2009, 166, 675–682. DOI: https://doi.org/10.1176/appi.ajp.2008.08060806
Schmid E.F., Smith D.A., Drug Discov. Today 2005, 10, 1031−1039. DOI: https://doi.org/10.1016/S1359-6446(05)03524-5
Wong E.H.F., Tarazi F.I., Shahid M. Pharmacolology & Therapeutics 2010, 126, 173–185. DOI: https://doi.org/10.1016/j.pharmthera.2010.02.001
Wong E.H.F., Nikam S.S., Shahid M. Curr. Opin. Investig. Drugs 2008, 9, 28−36.
Schreiber R., Newman-Tancredi A. Neurobiol. of Learn. and Mem. 2014, 110, 72–80.
Preskorn S.H., Lacey R.L., J. Psychiatr. Pract. 2007, 13, 97−105. DOI: https://doi.org/10.1097/01.pra.0000265766.25495.3b
Bishara D., Taylor D. Drugs 2008, 68, 2269−2292. DOI: https://doi.org/10.2165/0003495-200868160-00002
Hedlund P.B., Sutcliffe J. G. Trends Pharmacol. Sci. 2004, 25, 481–486. DOI: https://doi.org/10.1016/j.tips.2004.07.002
Schreiber R., Newman-Tancredi A. Neurobiol. of Learn. and Mem. 2014, 110, 72–80. DOI: https://doi.org/10.1016/j.nlm.2013.12.015
Newman-Tencredi A., Kleven M. Arch. Psychiatr. Psychother., 2010, 4, 5–11.
Słowiński T., Stefanowicz J., Dawidowski M., Kleps J., Czuczwar S., Andres-Mach M., Łuszczki J. J., Nowak G., Stachowicz K., Szewczyk B., Sławińska A., Mazurek A., Pluciński F., Wolska I., Herold F., Eur. J. Med. Chem. 2011, 46, 4474–4488. DOI: https://doi.org/10.1016/j.ejmech.2011.07.022
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
